Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Janice Lookabaugh"'
Autor:
Admir Hadzic, Richard D Berkowitz, Forrest G. Ringold, Timothy I. Melson, Brian M. Ilfeld, Harold S. Minkowitz, Anna Uskova, Janice Lookabaugh
Publikováno v:
Hadzic, A; Minkowitz, HS; Melson, TI; Berkowitz, R; Uskova, A; Ringold, F; et al.(2016). Liposome Bupivacaine Femoral Nerve Block for Postsurgical Analgesia after Total Knee Arthroplasty. ANESTHESIOLOGY, 124(6), 1372-1383. doi: 10.1097/ALN.0000000000001117. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/5rv5z8cx
Anesthesiology, vol 124, iss 6
Anesthesiology, vol 124, iss 6
BackgroundThe authors evaluated the efficacy of liposome bupivacaine in a femoral nerve block (FNB) after total knee arthroplasty.MethodsPart 1: subjects received FNB with 20 ml liposome bupivacaine (67, 133, or 266 mg) or placebo. Part 2: subjects w
Autor:
Janice Lookabaugh, Brian M. Ilfeld, Admir Hadzic, Girish P. Joshi, Michael Morren, Harold S. Minkowitz, Eugene R. Viscusi
Publikováno v:
Regional anesthesia and pain medicine, vol 40, iss 5
Ilfeld, BM; Viscusi, ER; Hadzic, A; Minkowitz, HS; Morren, MD; Lookabaugh, J; et al.(2015). Safety and Side Effect Profile of Liposome Bupivacaine (Exparel) in Peripheral Nerve Blocks. Regional Anesthesia and Pain Medicine, 40(5), 572-582. doi: 10.1097/AAP.0000000000000283. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/8m32493m
Ilfeld, BM; Viscusi, ER; Hadzic, A; Minkowitz, HS; Morren, MD; Lookabaugh, J; et al.(2015). Safety and Side Effect Profile of Liposome Bupivacaine (Exparel) in Peripheral Nerve Blocks. Regional Anesthesia and Pain Medicine, 40(5), 572-582. doi: 10.1097/AAP.0000000000000283. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/8m32493m
© 2015 American Society of Regional Anesthesia and Pain Medicine. Background Liposome bupivacaine (Exparel) is a multivesicular liposomal formulation of bupivacaine currently approved in the United States for single-dose administration into the surg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::471352fdda78603b2ba81cfaca9ef279
https://escholarship.org/uc/item/8m32493m
https://escholarship.org/uc/item/8m32493m
Autor:
Rainer Brase, Robert A. Balk, John Pribble, Maire P. Shelly, John F. LaBrecque, Klaus Matzel, Steven M. Opal, Jerald C. Sadoff, Jean-François Dhainaut, Gus J. Slotman, Robert P. Baughman, James Norman, Stephen F. Lowry, Edward Abraham, Michael G. Seneff, Charles J. Fisher, Howard Dubin, Hugh Donovan, Jean Louis Vincent, Janice Lookabaugh, Eric J. DeMaria, Howard Levy
Publikováno v:
Critical Care Medicine. 25:1115-1124
Objective: To determine the therapeutic efficacy and safety of recombinant human interleukin-1 receptor antagonist (rhlL-1ra) in the treatment of patients with severe sepsis. Design: Prospective, randomized, double-blind, placebo-controlled, multicen